Associations of filaggrin gene loss-of-function variants and human papillomavirus-related cancer and pre-cancer in Danish adults

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Skaaby, Tea ^a   Husemoen, Lise Lotte N ^a   Jørgensen, Torben ^a,b,c   Johansen, Jeanne D ^d   Menné, Torkil ^d   Szecsi, Pal B ^d   Stender, Steen ^d   Bager, Peter ^e   Thyssen, Jacob P ^d   Linneberg, Allan ^a,b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e National Institute for Health Data and Disease Control   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

FILAGGRIN; INTERMEDIATE FILAMENT PROTEIN;

ADULT; ANUS CANCER; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; DENMARK; FEMALE; FLG GENE; GENETIC ASSOCIATION; GENOTYPE; HEAD AND NECK CANCER; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; PENIS CANCER; PRECANCER; PREVALENCE; UTERINE CERVIX CANCER; VAGINA CANCER; VIRUS CARCINOGENESIS; VULVA CANCER; WART VIRUS; ADOLESCENT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RANDOMIZED CONTROLLED TRIAL; REGISTER; VIROLOGY;

ADOLESCENT; ADULT; AGED; DENMARK; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MALE; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; REGISTRIES;

EID: 84902579147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099437     Document Type: Article

References (33)

1. Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24 Suppl 3: S3-11-S3/25.
2. Ferlay J, Soerjomataram I, Ervik M, Eser S, Parkin DM, et al. (2012) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 2013. 13-12-2013.
3. Skaaby S, Kofoed K (2011) Anogenital warts in Danish men who have sex with men. Int J STD AIDS 22: 214-7.
4. Gong JM, Shen Y, He YX, Lei DM, Zhang Z, Li XF (2012) New technology for cervical cancer screening. Int J Gynecol Cancer 22: 1564-9.
5. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions (2007) N Engl J Med 356: 1915-27.
6. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-43. (Pubitemid 46740303)
7. Irvine AD, McLean WH, Leung DY (2011) Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 365: 1315-27.
8. De BA, Qualia CM, Baroody FM, Beck LA (2008) Filaggrin expression in oral, nasal, and esophageal mucosa. J Invest Dermatol 128: 1594-7. (Pubitemid 351693198)
9. Thyssen JP, Linneberg A, Carlsen BC, Johansen JD, Engkilde K, et al. (2011) A possible association between a dysfunctional skin barrier (filaggrin null-mutation status) and diabetes: a cross-sectional study. BMJ Open 1: e000062.
10. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38: 441-6.
11. Mildner M, Jin J, Eckhart L, Kezic S, Gruber F, et al. (2010) Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. J Invest Dermatol 130: 2286-94.
12. Carrillo-Infante C, Abbadessa G, Bagella L, Giordano A (2007) Viral infections as a cause of cancer (review). Int J Oncol 30: 1521-8.
13. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30: 1073-81.
14. Grivennikov SI, Karin M (2010) Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20: 65-71.
15. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, et al. (2007) N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28: 1374-81. (Pubitemid 47355969)
16. Jorgensen T, Borch-Johnsen K, Thomsen TF, Ibsen H, Glumer C, et al. (2003) A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 10: 377-86. (Pubitemid 38037253)
17. Berg ND, Husemoen LL, Thuesen BH, Hersoug LG, Elberling J, et al. (2012) Interaction between filaggrin null mutations and tobacco smoking in relation to asthma. J Allergy Clin Immunol 129: 374-80, 380.
18. Husemoen LL, Fenger M, Friedrich N, Tolstrup JS, Beenfeldt FS, et al. (2008) The association of ADH and ALDH gene variants with alcohol drinking habits and cardiovascular disease risk factors. Alcohol Clin Exp Res 32: 1984-91.
19. Meldgaard M, Szecsi PB, Carlsen BC, Thyssen JP, Johansen JD, et al. (2012) A novel multiplex analysis of filaggrin polymorphisms: A universally applicable method for genotyping. Clin Chim Acta 413: 1488-92.
20. Husemoen LL, Skaaby T, Jorgensen T, Thyssen JP, Meldgaard M, et al. (2013) No Association between Loss-of-Function Mutations in filaggrin and Diabetes, Cardiovascular Disease, and All-Cause Mortality. PLoS One 8: e84293.
21. Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39: 42-5.
22. Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 44: 535-9.
23. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39: 22-5.
24. Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, et al. (2008) Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 113: 2901-9.
25. Cintorino M, Syrjanen S, Leoncini P, Bellizzi De ME, Petracca R, et al. (1988) Altered expression of filaggrin in human papillomavirus (HPV) lesions of the uterine cervix. Arch Gynecol Obstet 241: 235-47. (Pubitemid 18071083)
26. Lara C, Serra V, Marzo C, Valcuende F, Castells A, et al. (1994) Immunohistochemical localization of filaggrin in benign, premalignant and malignant cervical tissue. Arch Gynecol Obstet 255: 73-9. (Pubitemid 24194220)
27. Skaaby T, Husemoen LL, Martinussen T, Thyssen JP, Melgaard M, et al. (2013) Vitamin D status, filaggrin genotype, and cardiovascular risk factors: a Mendelian randomization approach. PLoS One 8: e57647.
28. Thyssen JP, Thuesen B, Huth C, Standl M, Carson CG, et al. (2012) Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations. J Allergy Clin Immunol 130: 1204-7.
29. van D, V, Alloul-Ramdhani M, Danso MO, Mieremet A, Mulder A, et al. (2013) Knock-down of filaggrin does not affect lipid organization and composition in stratum corneum of reconstructed human skin equivalents. Exp Dermatol 22: 807-12.
30. Boguniewicz M, Leung DY (2010) Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 125: 4-13.
31. Miajlovic H, Fallon PG, Irvine AD, Foster TJ (2010) Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus. J Allergy Clin Immunol 126: 1184-90.
32. Gao PS, Rafaels NM, Hand T, Murray T, Boguniewicz M, et al. (2009) Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. J Allergy Clin Immunol 124: 507-13, 513.
33. Mager DL (2006) Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med 4: 14.